Developed by researchers at Asan Medical Center in Seoul, a new cell-free DNA blood test utilizes artificial intelligence to screen for colorectal cancer with a diagnostic sensitivity of 90.4%. The liquid biopsy method detects microscopic genetic fragments shed by tumors into the bloodstream, offering an alternative to traditional stool tests and colonoscopies.
Colorectal cancer remains the third most commonly diagnosed malignancy in South Korea, yet it boasts a five-year survival rate exceeding 95% when caught early, according to clinical data published this month. Despite these favorable prognoses for localized disease, patient compliance with conventional screening methods stays low. National screening statistics indicate that only about 44% of eligible adults aged 50 and older undergo standard colorectal examinations, positioning the country near the bottom among major cancer screening categories.
By examining a single routine blood draw, the technology aims to capture pre-malignant lesions and early-stage tumors long before symptoms manifest.
In Plain English: The Clinical Takeaway
- Liquid Biopsy Mechanism: The assay isolates tiny fragments of genetic material released by dying cancer cells into the bloodstream, analyzing them through machine learning algorithms to flag malignant mutations.
- Minimally Invasive Impact: Requiring only a standard venipuncture rather than dietary restrictions or cathartic bowel preparation, the blood test could dramatically boost participation rates among reluctant populations.
Evaluating Diagnostic Sensitivity and Stage-Specific Efficacy
The clinical validation study spanned a total of 1,677 individuals, comprising 302 confirmed colorectal cancer patients, 108 subjects with advanced colorectal polyps, and 1,267 healthy controls. When processing the genetic sequencing data through their proprietary AI architecture, the investigators recorded an overall sensitivity of 90.4%. This figure notably surpasses the performance of standard national stool-based screening, known as the fecal occult blood test, which typically yields a sensitivity range between 70% and 80%.
Specificity—the statistical probability that a healthy person without disease will test negative—reached 94.7% in the trial cohort. Furthermore, when analyzing performance across distinct pathological stages, the assay demonstrated progressive efficacy aligned with tumor burden. Diagnostic sensitivity stood at 84.2% for Stage I, 85.0% for Stage II, 94.4% for Stage III, and scaled up to 100% for Stage IV disease. For advanced colorectal polyps, considered the primary pre-cancerous lesion pathway, the blood test successfully detected 58.3% of cases, outperforming the benchmark historically associated with stool collection assays.
| Metric / Subgroup | Cell-Free DNA Blood Test | Traditional Stool Test (FOBT) |
|---|---|---|
| Overall Sensitivity | 90.4% | 70% – 80% |
| Test Specificity | 94.7% | Varies by assay |
| Advanced Polyp Detection | 58.3% | 25% – 40% |
| Patient Preparation | Routine venous blood draw | Direct stool sample collection |
With incidence rates climbing among younger demographics aged 20 to 40, combining blood-based convenience with machine learning analytics provides a vital tool for interception. Catching these lesions early opens the door to minimally invasive endoscopic resection, preserving patient quality of life and avoiding major surgical interventions.
Contraindications & When to Consult a Doctor
A positive result on a cell-free DNA blood test does not constitute a definitive histological diagnosis; it serves as a screening triage indicator that mandates confirmatory diagnostic evaluation via standard optical colonoscopy.
References
- Asan Medical Center. Clinical trial data on artificial intelligence-driven cell-free DNA blood diagnostics for colorectal cancer screening.
